At the physiological level, biologic therapies contribute to the reduction in type 2 inflammation by targeting specific cytokines (IL-4, IL-5, IL-13) and IgE, leading to decreased airway hyperresponsiveness, reduced mucus production, and improved lung function [34,92,93,94]. The gene discussed is IL5; the disease is airway hyperresponsiveness.